Charlotte Lynne Bevan

27PUBLICATIONS
39CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer geneticsMedical biotechnology diagnostics (incl. biosensors)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Jul 17, 2026
Author Correction: Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells.

|May 29, 2026
Molecular determinants of AR-enhancer interaction and cistrome reprogramming in prostate cancer progression.

|Feb 06, 2026
Disruption of androgen receptor-cofactor interactions by the RNA-binding protein FUS/TLS alters androgen signalling in prostate cancer.

G N Brooke, D A Leach, R L Culley

|Jan 12, 2026
Fat's all, folks: culturing and manipulating peri-prostatic adipocytes to probe impacts on prostate cancer biology.

Nil Grunberg, Mathias Winkler, Giles Hellawell

|Sep 08, 2025
Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells.

Chun-Fui Lai, Victoria I Cushing, Ellen Olden

|Jul 11, 2025
Thieno[2,3-b]pyridine compounds potently inhibit prostate cancer growth and motility.

M A Alkheilewi, D A Leach, A Mohr

Pageof 5

Frequent Collaborators

6 joint publications

Damien A Leach

5 joint publications

Claire Emily Fletcher

4 joint publications

Simak Ali

3 joint publications

G N Brooke